Inhaled nitric oxide increases coronary artery patency after thrombolysis

Circulation

Volumn 94, Issue 8, 1996, Pages 1919-1926

  Adrie, Christophe ^a   Bloch, Kenneth D ^a   Moreno, Pedro R ^a   Hurford, William E ^a   Guerrero, J Luis ^a   Holt, Robert ^a   Zapol, Warren M ^a   Gold, Herman K ^a   Semigran, Marc J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

nitric oxide; thrombolysis; thrombus

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; HEPARIN; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; THROMBIN; THROMBOXANE RECEPTOR STIMULATING AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DOG; FEMALE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; VASODILATATION;

EID: 0029825135     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.8.1919     Document Type: Article

References (40)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome, part 1. N Engl J Med. 1992;326:242-250.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome, part 2. N Engl J Med. 1992;326:310-318.
3. Coller BS. Platelets and thromboiytic therapy. N Engl J Med. 1990;322:33-42.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
6. Gold HK, Yasuda T, Jang TK, Guerrero L, Fallon JT, Leinbach RC, Collen D. Animal models for arterial thrombolysis and prevention of reocclusion: erythrocyte-rich versus platelet-rich thrombus. Circulation, 1991;83(suppl IV):IV-26-IV-40.
7. Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation. 1990;83:1038-1047.
8. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1-21.
9. Holzmann S. Endothelium-induced relaxation by acetylcholine associated with large rises in cGMP in coronary arterial strips. J Cyclic Nucl Res. 1982;8:409-419.
10. Ignarro LJ, Burke TM, Wood KS, Wolin MS, Kadowitz PJ. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J Pharmacol Exp Ther. 1983;228:682-690.
11. Radowski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193-5197.
12. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Inhibition of human platelet aggregation by S-nitrosothiols: heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol. 1983;23:653-664.
13. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57:946-955.
14. Folts JD, Stamler J, Loscalzo J. Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation. 1991;83:2122-2127.
15. Rovin JD, Stamler JS, Loscalzo J, Folts JD. Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries. J Cardiovasc Pharmacol. 1993;22:626-631.
16. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991;83:2038-2047.
17. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Walwork J. Inhaled nitric oxide as a cause of selective vasodilation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
18. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
19. Semigran MJ, Cockrill BA, Kacmarek R, Thompson BT, Zapol M, Dec GM, Fifer MA. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol. 1994;24:982-988.
20. Cassoly R, Gibson Q. Conformation, co-operativity and ligand binding in human hemoglobin. J Mol Biol. 1975;91:301-313.
21. Rimar S, Gillis N. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation. 1993;88:2884-2887.
22. Högman M, Frostell C, Arnberg H, Sandhagen B, Hedenstierna G. Bleeding time prolongation and nitric oxide inhalation. Lancet. 1993;341:1664-1665.
23. Högman M, Frostell C, Arnberg H, Sandhagen B, Hedenstierna G. Prolonged bleeding time during nitric oxide inhalation in the rabbit. Acta Physiol Scand. 1994;151:125-129.
24. Fontjin A, Sabadell AJ, Ronco RJ. Homogeneous chemiluminescent measurement of nitric oxide with ozone. Anal Chem. 1970;42:575-579.
25. Hatterley PG. Activated coagulation time of whole blood. JAMA. 1966;196:436-440.
26. 4 on coronary circulation and myocardial contractility. Surgery. 1983;94:267-274.
27. Keaney JF, Simon DI, Stamler JS, Jaraki O, Scharfstein J, Vita JA, Loscalzo J. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest. 1993;91:1582-1589.
28. Collen D, Lu HR, Stassen JM, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost. 1994;71:95-102.
29. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318:1714-1719.
30. Werns SW, Rote WE, Davis JH, Guevara T, Lucchesi BR. Nitroglycerin inhibits experimental thrombosis and reocciusion after thrombolysis. Am Heart J. 1994;127:727-737.
31. Yao SK, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, Buja LM. Willerson JT. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation. 1992;86:1302-1309.
32. Golino P, Cappelli-Bigazzi M, Ambrosio G, Ragni M, Russolillo E, Condorelli M, Chiariello M. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ Res. 1992;71:1447-1456.
33. Golino P, Ashton JH, Buja LM, Rosolowsky M, Taylor AL, McNatt J, Campbell WB, Willerson JT. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Circulation. 1989;79:154-166.
34. Tschopp JF, Bell DJ, Bunting S. Novel RGD-based glycoprotein IIb/IIIa receptor antagonists as antithrombotics. Blood. 1992;80(suppl I):320a. Abstract.
35. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol. 1990;16:714-722.
36. Mulligan MS, Hevel JM, Marletta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A. 1991;88:6338-6342.
37. Kooy NW, Royall JA, Ye YZ, Kelly DR, Beckman JS. Evidence for in vivo peroxynitrite production in human acute lung injury. Am J Respir Crit Care Med. 1995;151:1250-1254.
38. Mayer B, Klatt P, Werner ER, Schmidt K. Kinetics and mechanism of tetrahydrobiopterin-induced oxidation of nitric oxide. J Biol Chem. 1995;270:655-659.
39. Moro MA, Darley-Usmar VM, Goodwin DA, Read NG, Zamora-Pino R, Feelisch M, Radomski MW, Moncada S. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci U S A, 1994;91:6702-6706.
40. Kim YM, Bergonia HA, Muller C, Pitt BR, Watkins WD, Lancaster JR. Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis. J Biol Chem. 1995;270:5710-5713.